Loading cancer entity…
Loading cancer entity…
Clinical trials
805 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07165886 | Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors | recruiting | Phase 2 / Phase 3 | 298 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Apr 24, 2026 | clinicaltrials |
| NCT02174549 | Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer | recruiting | Phase 1 / Phase 2 | 25 | Teclison Ltd.INDUSTRY | 1 | Apr 20, 2026 |
| clinicaltrials |
| NCT04074135 | Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors | recruiting | Phase 2 | 740 | National Cancer Institute (NCI)NIH | 1 | Apr 20, 2026 | clinicaltrials |
| NCT05969860 | At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer | recruiting | Phase 2 | 220 | Mayo ClinicOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT07536087 | Endoscopic Ultrasound-Guided Radiofrequency Ablation for Pancreatic Cystic Neoplasms and Pancreatic Neuroendocrine Tumors | recruiting | N/A | 50 | Institute for Clinical and Experimental MedicineOTHER_GOV | 1 | Apr 17, 2026 | clinicaltrials |
| NCT07534371 | Analysis of Optimal Treatment Sequencing of Surufatinib and Somatostatin Analogs in Neuroendocrine Tumors: A Retrospective Cohort Study | active not recruiting | — | 500 | West China HospitalOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT05153772 | Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients(ALPHAMEDIX02) | active not recruiting | Phase 2 | 69 | Orano Med LLCINDUSTRY | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06638931 | Agnostic Therapy in Rare Solid Tumors(ANTARES) | recruiting | Phase 2 | 28 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05249114 | Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors | active not recruiting | Phase 1 | 6 | Providence Health & ServicesOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT04291885 | Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma(I-MAT) | active not recruiting | Phase 2 | 122 | Melanoma and Skin Cancer Trials LimitedOTHER | 2 | Apr 9, 2026 | clinicaltrials |
| NCT04569591 | DDAVP for Pituitary Adenoma | recruiting | N/A | 22 | National Institute of Neurological Disorders and Stroke (NINDS)NIH | 1 | Apr 9, 2026 | clinicaltrials |
| NCT05048901 | Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors | recruiting | Phase 1 / Phase 2 | 49 | National Health Research Institutes, TaiwanOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT06141369 | Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001) | recruiting | N/A | 21 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT05477576 | Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy(ACTION-1) | recruiting | Phase 3 | 338 | RayzeBio, Inc.INDUSTRY | 8 | Mar 30, 2026 | clinicaltrials |
| NCT05847855 | Plasma cfDNA Fragmentomics for Early pNET Detection and Differential Diagnosis of Solid Pancreatic Tumors | recruiting | — | 1,000 | Fudan UniversityOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT04804371 | Dual Tracer (68Ga-DOTATATE and 18F-FDG) PET Imaging in G2 & G3 Gastroenteropancreatic Neuroendocrine Tumors | active not recruiting | N/A | 40 | University Health Network, TorontoOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT04090034 | Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors(PRRT) | recruiting | — | 50 | Methodist Health SystemOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT05500391 | Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring(SUR-CAN) | recruiting | Phase 2 | 88 | Centre Oscar LambretOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT04119024 | Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors | recruiting | Phase 1 | 18 | Anusha KalbasiOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT05746208 | Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors | recruiting | Phase 2 | 29 | University of California, San FranciscoOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT07463235 | Safety and Potency of a High Cabergoline Dosage in Microprolactinomas(SPARAGMOS) | recruiting | Phase 3 | 70 | University of Sao Paulo General HospitalOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT07463872 | Management of Pancreatic Cystic Lesions Using Artificial Intelligence Based on EUS and Multimodal Data | recruiting | — | 500 | Huazhong University of Science and TechnologyOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT05160480 | A Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDG | enrolling by invitation | — | 9 | University of California, DavisOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT00830557 | Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders | recruiting | — | 20,000 | Mayo ClinicOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT07456878 | Use of [18F] Fluoroethyl-L-tyrosine PET/MRI for Identifying Small Functional Pituitary Adenomas | recruiting | Phase 1 | 5 | Mayo ClinicOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT07450287 | CardioNETPOL National Registry of Carcinoid Heart Disease(CardioNETPOL) | not yet recruiting | — | 120 | National Institute of Cardiology, Warsaw, PolandOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT07446036 | Prediction Model for Postoperative Headache After Transsphenoidal Pituitary Surgery | active not recruiting | — | 500 | Beijing Tiantan HospitalOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07150546 | Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors. | recruiting | Phase 1 | 15 | Emory UniversityOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT04969887 | Combination Immunotherapy in Rare Cancers Under InvesTigation(MOST-CIRCUIT) | active not recruiting | Phase 2 | 240 | Olivia Newton-John Cancer Research InstituteOTHER | 2 | Feb 27, 2026 | clinicaltrials |
| NCT07439757 | AI-Powered Precision Decision-Making for Pancreatic Diseases | recruiting | — | 2,000 | Changhai HospitalOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT04907643 | Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes | recruiting | N/A | 360 | Cedars-Sinai Medical CenterOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT04278118 | Hypofractionated Proton Therapy for Benign Intracranial Brain Tumors, the HiPPI Study(HiPPI) | recruiting | N/A | 70 | Emory UniversityOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT04711135 | Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs(NETTER-P) | active not recruiting | Phase 2 | 11 | Advanced Accelerator ApplicationsINDUSTRY | 5 | Feb 12, 2026 | clinicaltrials |
| NCT07404176 | Study to Assess the Safety and Effectiveness of Novel Radiopharmaceutical Terbium-161 DOTATATE in Metastatic Neuroendocrine Tumors(TENET) | recruiting | Phase 2 | 20 | Tata Memorial HospitalOTHER_GOV | 1 | Feb 11, 2026 | clinicaltrials |
| NCT04706910 | 18F-DOPA II - PET Imaging Optimization | recruiting | Phase 3 | 800 | University of AlbertaOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT06055439 | A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy | recruiting | Phase 1 / Phase 2 | 135 | Chimeric TherapeuticsINDUSTRY | 1 | Jan 29, 2026 | clinicaltrials |
| NCT07373015 | Modified Double Snare Assisted EMR (mDS-EMR) VS ESD for Rectal Neuroendocrine Tumors Smaller Than 1cm | not yet recruiting | N/A | 118 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 0 | Jan 28, 2026 | clinicaltrials |
| NCT07369505 | Sapu003 in Advanced mTOR-sensitive Solid Tumors | recruiting | Phase 1 | 27 | SAPU NANO (US) LLCINDUSTRY | 1 | Jan 27, 2026 | clinicaltrials |
| NCT05556473 | F-Tryptophan PET/CT in Human Cancers | recruiting | Phase 1 | 24 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT07268183 | How Estrogen Fluctuations Before Diagnosis Affect the Size Prolactin-secreting Tumors(OEMacroPrL) | recruiting | — | 180 | Hospices Civils de LyonOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT07273409 | Pancreatic Neuroendocrine Tumour - Optimal Surgical Debulking or Not(PANTODON) | recruiting | N/A | 200 | Uppsala UniversityOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT07328607 | Outcomes After Laparoscopic Versus Open Pancreaticoduodenectomy | recruiting | N/A | 90 | Minia UniversityOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT06356467 | Influence of Tumour and Patient's Related Factors on the Response to Medical Treatments in Well Differentiated GEP-NENs(FARINET) | recruiting | — | 450 | IRCCS San RaffaeleOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT03891784 | Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors | active not recruiting | Phase 2 | 20 | University of WashingtonOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT06232564 | A Study of Etoposide-carboplatin in Combination With Pembrolizumab and Lenvatinib Maintenance in HG-NETs(PELICAN) | active not recruiting | Phase 2 | 20 | Imperial College LondonOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT05735912 | EUS-RFA Versus Surgery for Pancreatic Insulinoma (ERASIN-RCT)(ERASIN-RCT) | active not recruiting | N/A | 60 | Azienda Ospedaliera Universitaria Integrata VeronaOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT06406387 | ATRX/DAXX in EUS-FNB Specimens of Pan-NETs(FORESEE) | active not recruiting | — | 100 | Azienda Ospedaliera Universitaria Integrata VeronaOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT06663072 | Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors | recruiting | Phase 1 | 25 | University of ChicagoOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT06936813 | The PROMISE Survey | active not recruiting | — | 530 | University Hospital, Basel, SwitzerlandOTHER | 1 | Jan 8, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Apr 24, 2026source: clinicaltrials